Accessible Search Form           Advanced Search

  • PRINT  | 

Jay H. Chung, Ph.D., M.D.

Laboratory of Obesity and Aging Research

Jay H. Chung, Ph.D., M.D.
Senior Investigator
Laboratory of Obesity and Aging Research


Building 10 Room 7D14
10 Center Dr
Bethesda, MD 20892
P: +1 301 496 3075
F: +1 301 496 9985
chungj@nhlbi.nih.gov


Background

Jay Chung earned a B.S. in electrical engineering and a B.S. in biology from the Massachusetts Institute of Technology before receiving a M.D. and Ph.D. in genetics from Harvard Medical School, during which he received the James Tolbert Shipley Prize for Research in 1998. After an internship and residency in internal medicine at Brigham and Women’s Hospital, he became an endocrine fellow at the National Institute of Diabetes and Digestive and Kidney Diseases at the NIH where he worked with Gary Felsenfeld. He moved to the NHLBI in 1994 as an Investigator in the Laboratory of Biochemical Genetics.

Research Interests

Dr. Chung's primary research interest is in understanding how aging decreases our ability to burn calories and generate energy. This aging-related metabolic decline plays an important role in the development of obesity and obesity-related diseases such as type 2 diabetes and cardiovascular disease. Dr. Chung is working to understand the key molecular mechanisms that underlie the beneficial effects of caloric restriction in order to develop therapeutic strategies that mimic these effects and protect against metabolic diseases.

Dr. Chung’s laboratory is focused on two key enzyme pathways—Sirtuin 1 (SIRT1) and AMP-dependent kinase (AMPK)—that are linked with metabolic diseases as well as with the effects of caloric restriction. He and his colleagues use transgenic approaches in cells and mice to manipulate these pathways and to monitor the metabolic outcomes. For example, caloric restriction results in a shift from the utilization of carbohydrates to stored fats as the primary energy source. By examining mitochondrial levels and gene expression patterns in cells and tissues, it is possible to observe the shift towards fat burning that arises from different genetic perturbations.

Resveratrol, perhaps best known as a component of red wine, has been shown to mimic certain beneficial aspects of caloric restriction, including protection against type 2 diabetes. It is also a "dirty" compound in the sense that it activates several molecular pathways, some of which may be beneficial, others of which may prove toxic over the long term. Dr. Chung and his colleagues are studying the signaling pathways activated by resveratrol to tease apart their modes of action and discover the pathways that contribute to the prevention of type 2 diabetes. Using various animal models, they have demonstrated that while resveratrol does not directly target SIRT1, as previously proposed, it does inhibit phosphodiesterases (PDEs), which results in increased levels of the signaling molecule cAMP and activation of AMPK. They have been able to mimic the protective effects of resveratrol with a selective inhibitor of PDE4. This work was selected as a "best of 2012 paper" by Cell.

Recently, the FDA approved a drug that inhibits PDE4 for the treatment of chronic obstructive pulmonary disease (COPD). An incidental finding from the clinical trial was that COPD patients who happened to be diabetic had significantly lower blood glucose levels if they were on this inhibitor, thus confirming the effect Dr. Chung observed in animals. This has led Dr. Chung to initiate a clinical trial in subjects with pre-diabetes to investigate the glucose-lowering mechanism of PDE4 inhibition in humans.

Dr. Chung believes that many aging-related diseases that are not normally considered metabolic diseases are nonetheless related. For example, obesity and type 2 diabetes are significant risk factors for the development of Alzheimer’s disease in the elderly. His laboratory is bringing similar strategies to bear on the biochemical pathways that couple obesity, type 2 diabetes, and Alzheimer’s disease.

Selected Publications

Metabolic sensor AMPK directly phosphorylates RAG1 protein and regulates V(D)J recombination.
Um JH, Brown AL, Singh SK, Chen Y, Gucek M, Lee BS, Luckey MA, Kim MK, Park JH, Sleckman BP, Gellert M, Chung JH.
Proc Natl Acad Sci U S A..
[Text Abstract on PubMed]

Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases.
Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, Taussig R, Brown AL, Kim MK, Beaven MA, Burgin AB, Manganiello V, Chung JH.
Cell. 2012 Feb 3;148(3):421-33.
[Text Abstract on PubMed]

Peptide switch is essential for Sirt1 deacetylase activity.
Kang H, Suh JY, Jung YS, Jung JW, Kim MK, Chung JH.
Mol. Cell. 2011 Oct 21;44(2):203-13.
[Text Abstract on PubMed]

AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol.
Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, Kim MK, Viollet B, Chung JH.
Diabetes. 2010 Mar;59(3):554-63.
[Text Abstract on PubMed]

hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response.
Lee JS, Collins KM, Brown AL, Lee CH, Chung JH.
Nature. 2000 Mar 9;404(6774):201-4.
[Text Abstract on PubMed]

Jay H. Chung's Full List of Publications

DIR News
April 14, 2014
Henry Ford Hospital performs 25th transcaval valve replacementExternal link Disclaimer
March 12, 2014
Researchers find reason why many vein grafts fail
January 29, 2014
Correlative super-resolution fluorescence and transmission electron microscopyExternal link Disclaimer
December 23, 2013
President Obama honors outstanding early-career scientists
November 25, 2013
AAAS council elects 388 new AAAS FellowsExternal link Disclaimer

View all DIR News

Last Updated: December 19, 2013

Twitter iconTwitter         Facebook iconFacebook         YouTube iconYouTube        Google+ iconGoogle+